Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amicus Therapeutics
(NQ:
FOLD
)
10.62
+0.29 (+2.86%)
Streaming Delayed Price
Updated: 10:05 AM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
298,592
Open
10.27
Bid (Size)
10.62 (3)
Ask (Size)
10.63 (3)
Prev. Close
10.33
Today's Range
10.24 - 10.62
52wk Range
9.700 - 14.57
Shares Outstanding
266,555,274
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
Performance
YTD
-25.39%
-25.39%
1 Month
-10.26%
-10.26%
3 Month
-14.45%
-14.45%
6 Month
+3.26%
+3.26%
1 Year
-9.03%
-9.03%
More News
Read More
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
March 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
The Analyst Landscape: 4 Takes On Amicus Therapeutics
December 19, 2023
Via
Benzinga
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
February 15, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
February 09, 2024
Via
Investor's Business Daily
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
February 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
February 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
Via
MarketBeat
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
January 07, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
December 05, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
November 15, 2023
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
November 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 27, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 03, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
October 02, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
Via
Benzinga
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
September 28, 2023
Via
Benzinga
Exposures
Product Safety
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
September 28, 2023
Via
Investor's Business Daily
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
September 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 29, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.